ID: MRFR/HC/3065-CR | August 2021 | Region: Global | 100 Pages
TABLE OF CONTENTS
1 EXECUTIVE SUMMARY
1.1 MARKET ATTRACTIVENESS ANALYSIS
1.1.1 GLOBAL VAGAL NERVE STIMULATION MARKET, BY PRODUCTS, 2019
1.1.2 GLOBAL VAGAL NERVE STIMULATION MARKET, BY APPLICATION, 2019
1.1.3 GLOBAL VAGAL NERVE STIMULATION MARKET, BY END USER
1.1.4 GLOBAL VAGAL NERVE STIMULATION MARKET, BY REGION
2 MARKET INTRODUCTION
2.1 DEFINITION
2.2 SCOPE OF THE STUDY
2.3 MARKET STRUCTURE
3 RESEARCH METHODOLOGY
3.1 RESEARCH PROCESS
3.2 PRIMARY RESEARCH
3.3 SECONDARY RESEARCH
3.4 MARKET SIZE ESTIMATION
3.5 TOP DOWN & BOTTOM-UP APPROACH
3.6 FORECAST MODEL
3.7 LIST OF ASSUMPTIONS& LIMITATIONS
4 MARKET DYNAMICS
4.1 INTRODUCTION
4.2 DRIVERS
4.2.1 INCREASING PREVALENCE OF NEUROLOGICAL DISORDERS
4.2.2 INCREASING INVESTMENT OF BIOTECHNOLOGY AND PHARMACEUTICAL INDUSTRIES IN R&D
4.2.3 DRIVERS IMPACT ANALYSIS
4.3 RESTRAINTS
4.3.1 HIGHER COST OF VAGAL NERVE STIMULATIO TREATMENT PROCEDURE
4.3.2 RESTRAINTS IMPACT ANALYSIS
4.4 OPPORTUNITIES
4.4.1 INCREASING STRATEGIC MERGERS AND ACQUISITIONS
4.5 IMPACT OF COVID-19 ON THE GLOBAL VAGAL NERVE STIMULATION MARKET
4.5.1 IMPACT ON SUPPLY CHAIN
4.5.2 IMPACT ON PRODUCTION
4.5.3 IMPACT ON PRICING
5 MARKET FACTOR ANALYSIS
5.1 SUPPLY/VALUE CHAIN ANALYSIS
5.1.1 R&D
5.1.2 MANUFACTURING
5.1.3 DISTRIBUTION & SALES
5.1.4 POST-SALES MONITORING
5.2 PORTER’S FIVE FORCES MODEL
5.2.1 THREAT OF NEW ENTRANTS
5.2.2 BARGAINING POWER OF SUPPLIERS
5.2.3 BARGAINING POWER OF BUYERS
5.2.4 THREAT OF SUBSTITUTES
5.2.5 INTENSITY OF RIVALRY
5.3 GLOBAL VNS DEVICE NEWLY IMPLANTED & RE-IMPLANTED BY VOLUME
5.4 EUROPE VNS DEVICE NEWLY IMPLANTED & RE-IMPLANTED BY VOLUME
5.5 US VNS DEVICE NEWLY IMPLANTED & RE-IMPLANTED BY VOLUME
5.6 VNS DEVICE IMPLEMENTED PATIENTS, BY COUNTRY, 2019
6 GLOBAL VAGAL NERVE STIMULATION MARKET, BY PRODUCTS
6.1 OVERVIEW
6.2 IMPLANTABLE VNS DEVICES
6.3 EXTERNAL VNS DEVICES
7 GLOBAL VAGAL NERVE STIMULATION MARKET, BY APPLICATION
7.1 OVERVIEW
7.2 DEPRESSION
7.3 EPILEPSY
7.4 OTHERS
8 GLOBAL VAGAL NERVE STIMULATION MARKET, BY END USER
8.1 OVERVIEW
8.2 HOSPITALS
8.3 AMBULATORY SURGICAL CENTERS
8.4 OTHERS
9 GLOBAL VAGAL NERVE STIMULATION MARKET, BY REGION
9.1 OVERVIEW
9.2 NORTH AMERICA
9.2.1 US
9.2.2 CANADA.
9.3 EUROPE
9.3.1 GERMANY
9.3.2 FRANCE.
9.3.3 UK
9.3.4 ITALY
9.3.5 SPAIN.
9.3.6 REST OF EUROPE.
9.4 ASIA-PACIFIC
9.4.1 CHINA
9.4.2 INDIA.
9.4.3 JAPAN.
9.4.4 AUSTRALIA.
9.4.5 SOUTH KOREA.
9.4.6 REST OF ASIA-PACIFIC.
9.5 REST OF THE WORLD
9.5.1 MIDDLE EAST
9.5.2 AFRICA.
9.5.3 LATIN AMERICA
10 COMPETITIVE LANDSCAPE
10.1 COMPETITIVE OVERVIEW
10.2 GLOBAL VAGAL NERVE STIMULATION MARKET: COMPANY SHARE ANALYSIS
10.3 COMPETITIVE BENCHMARKING
10.4 MAJOR GROWTH STRATEGY IN THE GLOBAL VAGAL NERVE STIMULATION MARKET
10.5 THE LEADING PLAYER IN TERMS OF NUMBER OF DEVELOPMENTS IN GLOBAL VAGAL NERVE STIMULATION MARKET
10.6 KEY DEVELOPMENTS & GROWTH STRATEGIES
10.6.1 NEW PRODUCTS LAUNCH/SERVICE DEPLOYMENT
10.6.2 MERGER & ACQUISITION
10.6.3 COLLABORATION
10.7 MAJOR PLAYERS FINANCIAL MATRIX & MARKET RATIO
10.7.1 SALES & OPERATING INCOME
10.7.2 R&D EXPENDITURE
11 COMPANY PROFILES
11.1 LIVANOVA PLC
11.1.1 COMPANY OVERVIEW
11.1.2 FINANCIAL OVERVIEW
11.1.3 PRODUCTS OFFERED
11.1.4 KEY DEVELOPMENTS
11.1.5 SWOT ANALYSIS
11.1.6 KEY STRATEGIES
11.2 RESHAPE LIFESCIENCES, INC.
11.2.1 COMPANY OVERVIEW
11.2.2 FINANCIAL OVERVIEW
11.2.3 PRODUCTS OFFERED
11.2.4 KEY DEVELOPMENTS
11.2.5 SWOT ANALYSIS
11.2.6 KEY STRATEGIES
11.3 ELECTROCORE MEDICAL LLC
11.3.1 COMPANY OVERVIEW
11.3.2 FINANCIAL OVERVIEW
11.3.3 PRODUCTS OFFERED
11.3.4 KEY DEVELOPMENTS
11.3.5 SWOT ANALYSIS
11.3.6 KEY STRATEGIES
11.4 BOSTON SCIENTIFIC CORPORATION
11.4.1 COMPANY OVERVIEW
11.4.2 FINANCIAL OVERVIEW
11.4.3 PRODUCTS OFFERED
11.4.4 KEY DEVELOPMENTS
11.4.5 SWOT ANALYSIS
11.4.6 KEY STRATEGIES
11.5 NEUROMETRIX, INC.
11.5.1 COMPANY OVERVIEW
11.5.2 FINANCIAL OVERVIEW
11.5.3 PRODUCTS OFFERED
11.5.4 KEY DEVELOPMENTS
11.5.5 SWOT ANALYSIS
11.5.6 KEY STRATEGIES
11.6 IMTHERA MEDICAL INC.
11.6.1 COMPANY OVERVIEW
11.6.2 FINANCIAL OVERVIEW
11.6.3 PRODUCTS OFFERED
11.6.4 SWOT ANALYSIS
11.6.5 KEY STRATEGIES
11.7 INSPIRE MEDICAL SYSTEMS, INC.
11.7.1 COMPANY OVERVIEW
11.7.2 FINANCIAL OVERVIEW
11.7.3 PRODUCTS OFFERED
11.7.4 KEY DEVELOPMENTS
11.7.5 SWOT ANALYSIS
11.7.6 KEY STRATEGIES
11.8 PARASYM LTD
11.8.1 COMPANY OVERVIEW
11.8.2 FINANCIAL OVERVIEW
11.8.3 PRODUCTS OFFERED
11.8.4 KEY DEVELOPMENTS
11.8.5 SWOT ANALYSIS
11.8.6 KEY STRATEGIES
11.9 INNOVATIVE HEALTH SOLUTIONS INC.
11.9.1 COMPANY OVERVIEW
11.9.2 FINANCIAL OVERVIEW
11.9.3 PRODUCTS OFFERED
11.9.4 KEY DEVELOPMENTS
11.9.5 SWOT ANALYSIS
11.9.6 KEY STRATEGIES
12 APPENDIX
12.1 REFERENCES
12.2 RELATED REPORTS
 
LIST OF TABLES
TABLE 1 LIST OF ASSUMPTIONS& LIMITATIONS
TABLE 2 GLOBAL VNS DEVICE NEWLY IMPLANTED & RE-IMPLANTED BY VOLUME, 2016–2020 (UNITS)
TABLE 3 EUROPE VNS DEVICE NEWLY IMPLANTED & RE-IMPLANTED BY VOLUME, 2016–2020 (UNITS)
TABLE 4 US VNS DEVICE NEWLY IMPLANTED & RE-IMPLANTED BY VOLUME, 2016–2020 (UNITS)
TABLE 5 VNS DEVICE IMPLEMENTED PATIENTS, BY COUNTRY, 2019
TABLE 6 GLOBAL VAGAL NERVE STIMULATION MARKET, BY PRODUCTS, 2017–2027 (USD MILLION)
TABLE 7 GLOBAL VAGAL NERVE STIMULATION MARKET FOR IMPLANTABLE VNS DEVICES, BY REGION, 2017–2027 (USD MILLION)
TABLE 8 GLOBAL VAGAL NERVE STIMULATION MARKET FOR EXTERNAL VNS DEVICES, BY REGION, 2017–2027 (USD MILLION)
TABLE 9 GLOBAL VAGAL NERVE STIMULATION MARKET, BY APPLICATION, 2017–2027 (USD MILLION)
TABLE 10 GLOBAL VAGAL NERVE STIMULATION MARKET, BY DEPRESSION, BY REGION, 2017–2027 (USD MILLION)
TABLE 11 GLOBAL VAGAL NERVE STIMULATION MARKET, BY EPILEPSY, BY REGION, 2017–2027 (USD MILLION)
TABLE 12 GLOBAL VAGAL NERVE STIMULATION MARKET, BY OTHERS, BY REGION, 2017–2027 (USD MILLION)
TABLE 13 GLOBAL VAGAL NERVE STIMULATION MARKET, BY END USER, 2017–2027 (USD MILLION)
TABLE 14 GLOBAL VAGAL NERVE STIMULATION MARKET, BY HOSPITALS, BY REGION, 2017–2027 (USD MILLION)
TABLE 15 GLOBAL VAGAL NERVE STIMULATION MARKET, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2017–2027 (USD MILLION)
TABLE 16 GLOBAL VAGAL NERVE STIMULATION MARKET, BY OTHERS, BY REGION, 2017–2027 (USD MILLION)
TABLE 17 GLOBAL VAGAL NERVE STIMULATION MARKET, BY REGION, 2017-2027 (USD MILLION)
TABLE 18 NORTH AMERICA: VAGAL NERVE STIMULATION MARKET, BY COUNTRY, 2017-2027 (USD MILLION)
TABLE 19 NORTH AMERICA: VAGAL NERVE STIMULATION MARKET, BY PRODUCTS, 2017-2027 (USD MILLION)
TABLE 20 NORTH AMERICA: VAGAL NERVE STIMULATION MARKET, BYAPPLICATION, 2017-2027 (USD MILLION)
TABLE 21 NORTH AMERICA: VAGAL NERVE STIMULATION MARKET, BY END USER, 2017-2027 (USD MILLION)
TABLE 22 US: VAGAL NERVE STIMULATION MARKET, BY PRODUCTS, 2017-2027 (USD MILLION)
TABLE 23 US: VAGAL NERVE STIMULATION MARKET, BYAPPLICATION, 2017-2027 (USD MILLION)
TABLE 24 US: VAGAL NERVE STIMULATION MARKET, BY END USER, 2017-2027 (USD MILLION)
TABLE 25 CANADA: VAGAL NERVE STIMULATION MARKET, BY PRODUCTS, 2017-2027 (USD MILLION)
TABLE 26 CANADA: VAGAL NERVE STIMULATION MARKET, BYAPPLICATION, 2017-2027 (USD MILLION)
TABLE 27 CANADA: VAGAL NERVE STIMULATION MARKET, BY END USER, 2017-2027 (USD MILLION)
TABLE 28 EUROPE: VAGAL NERVE STIMULATION MARKET, BY COUNTRY, 2017-2027 (USD MILLION)
TABLE 29 EUROPE: VAGAL NERVE STIMULATION MARKET, BY PRODUCTS, 2017-2027 (USD MILLION)
TABLE 30 EUROPE: VAGAL NERVE STIMULATION MARKET, BYAPPLICATION, 2017-2027 (USD MILLION)
TABLE 31 EUROPE: VAGAL NERVE STIMULATION MARKET, BY END USER, 2017-2027 (USD MILLION)
TABLE 32 GERMANY: VAGAL NERVE STIMULATION MARKET, BY PRODUCTS, 2017-2027 (USD MILLION)
TABLE 33 GERMANY: VAGAL NERVE STIMULATION MARKET, BYAPPLICATION, 2017-2027 (USD MILLION)
TABLE 34 GERMANY: VAGAL NERVE STIMULATION MARKET, BY END USER, 2017-2027 (USD MILLION)
TABLE 35 FRANCE: VAGAL NERVE STIMULATION MARKET, BY PRODUCTS, 2017-2027 (USD MILLION)
TABLE 36 FRANCE: VAGAL NERVE STIMULATION MARKET, BYAPPLICATION, 2017-2027 (USD MILLION)
TABLE 37 FRANCE: VAGAL NERVE STIMULATION MARKET, BY END USER, 2017-2027 (USD MILLION)
TABLE 38 UK: VAGAL NERVE STIMULATION MARKET, BY PRODUCTS, 2017-2027 (USD MILLION)
TABLE 39 UK: VAGAL NERVE STIMULATION MARKET, BYAPPLICATION, 2017-2027 (USD MILLION)
TABLE 40 UK: VAGAL NERVE STIMULATION MARKET, BY END USER, 2017-2027 (USD MILLION)
TABLE 41 ITALY: VAGAL NERVE STIMULATION MARKET, BY PRODUCTS, 2017-2027 (USD MILLION)
TABLE 42 ITALY: VAGAL NERVE STIMULATION MARKET, BYAPPLICATION, 2017-2027 (USD MILLION)
TABLE 43 ITALY: VAGAL NERVE STIMULATION MARKET, BY END USER, 2017-2027 (USD MILLION)
TABLE 44 SPAIN: VAGAL NERVE STIMULATION MARKET, BY PRODUCTS, 2017-2027 (USD MILLION)
TABLE 45 SPAIN: VAGAL NERVE STIMULATION MARKET, BYAPPLICATION, 2017-2027 (USD MILLION)
TABLE 46 SPAIN: VAGAL NERVE STIMULATION MARKET, BY END USER, 2017-2027 (USD MILLION)
TABLE 47 REST OF EUROPE: VAGAL NERVE STIMULATION MARKET, BY PRODUCTS, 2017-2027 (USD MILLION)
TABLE 48 REST OF EUROPE: VAGAL NERVE STIMULATION MARKET, BYAPPLICATION, 2017-2027 (USD MILLION)
TABLE 49 REST OF EUROPE: VAGAL NERVE STIMULATION MARKET, BY END USER, 2017-2027 (USD MILLION)
TABLE 50 ASIA-PACIFIC: VAGAL NERVE STIMULATION MARKET, BY COUNTRY, 2017-2027 (USD MILLION)
TABLE 51 ASIA-PACIFIC: VAGAL NERVE STIMULATION MARKET, BY PRODUCTS, 2017-2027 (USD MILLION)
TABLE 52 ASIA-PACIFIC: VAGAL NERVE STIMULATION MARKET, BYAPPLICATION, 2017-2027 (USD MILLION)
TABLE 53 ASIA-PACIFIC: VAGAL NERVE STIMULATION MARKET, BY END USER, 2017-2027 (USD MILLION)
TABLE 54 CHINA: VAGAL NERVE STIMULATION MARKET, BY PRODUCTS, 2017-2027 (USD MILLION)
TABLE 55 CHINA: VAGAL NERVE STIMULATION MARKET, BYAPPLICATION, 2017-2027 (USD MILLION)
TABLE 56 CHINA: VAGAL NERVE STIMULATION MARKET, BY END USER, 2017-2027 (USD MILLION)
TABLE 57 INDIA: VAGAL NERVE STIMULATION MARKET, BY PRODUCTS, 2017-2027 (USD MILLION)
TABLE 58 INDIA: VAGAL NERVE STIMULATION MARKET, BYAPPLICATION, 2017-2027 (USD MILLION)
TABLE 59 INDIA: VAGAL NERVE STIMULATION MARKET, BY END USER, 2017-2027 (USD MILLION)
TABLE 60 JAPAN: VAGAL NERVE STIMULATION MARKET, BY PRODUCTS, 2017-2027 (USD MILLION)
TABLE 61 JAPAN: VAGAL NERVE STIMULATION MARKET, BYAPPLICATION, 2017-2027 (USD MILLION)
TABLE 62 JAPAN: VAGAL NERVE STIMULATION MARKET, BY END USER, 2017-2027 (USD MILLION)
TABLE 63 AUSTRALIA: VAGAL NERVE STIMULATION MARKET, BY PRODUCTS, 2017-2027 (USD MILLION)
TABLE 64 AUSTRALIA: VAGAL NERVE STIMULATION MARKET, BYAPPLICATION, 2017-2027 (USD MILLION)
TABLE 65 AUSTRALIA: VAGAL NERVE STIMULATION MARKET, BY END USER, 2017-2027 (USD MILLION)
TABLE 66 SOUTH KOREA: VAGAL NERVE STIMULATION MARKET, BY PRODUCTS, 2017-2027 (USD MILLION)
TABLE 67 SOUTH KOREA: VAGAL NERVE STIMULATION MARKET, BYAPPLICATION, 2017-2027 (USD MILLION)
TABLE 68 SOUTH KOREA: VAGAL NERVE STIMULATION MARKET, BY END USER, 2017-2027 (USD MILLION)
TABLE 69 REST OF ASIA-PACIFIC: VAGAL NERVE STIMULATION MARKET, BY PRODUCTS, 2017-2027 (USD MILLION)
TABLE 70 REST OF ASIA-PACIFIC: VAGAL NERVE STIMULATION MARKET, BYAPPLICATION, 2017-2027 (USD MILLION)
TABLE 71 REST OF ASIA-PACIFIC: VAGAL NERVE STIMULATION MARKET, BY END USER, 2017-2027 (USD MILLION)
TABLE 72 REST OF THE WORLD: VAGAL NERVE STIMULATION MARKET, BY REGION, 2017-2027 (USD MILLION)
TABLE 73 REST OF THE WORLD: VAGAL NERVE STIMULATION MARKET, BY PRODUCTS, 2017-2027 (USD MILLION)
TABLE 74 REST OF THE WORLD: VAGAL NERVE STIMULATION MARKET, BYAPPLICATION, 2017-2027 (USD MILLION)
TABLE 75 REST OF THE WORLD: VAGAL NERVE STIMULATION MARKET, BY END USER, 2017-2027 (USD MILLION)
TABLE 76 MIDDLE EAST: VAGAL NERVE STIMULATION MARKET, BY PRODUCTS, 2017-2027 (USD MILLION)
TABLE 77 MIDDLE EAST: VAGAL NERVE STIMULATION MARKET, BYAPPLICATION, 2017-2027 (USD MILLION)
TABLE 78 MIDDLE EAST: VAGAL NERVE STIMULATION MARKET, BY END USER, 2017-2027 (USD MILLION)
TABLE 79 AFRICA: VAGAL NERVE STIMULATION MARKET, BY PRODUCTS, 2017-2027 (USD MILLION)
TABLE 80 AFRICA: VAGAL NERVE STIMULATION MARKET, BYAPPLICATION, 2017-2027 (USD MILLION)
TABLE 81 AFRICA: VAGAL NERVE STIMULATION MARKET, BY END USER, 2017-2027 (USD MILLION)
TABLE 82 LATIN AMERICA: VAGAL NERVE STIMULATION MARKET, BY PRODUCTS, 2017-2027 (USD MILLION)
TABLE 83 LATIN AMERICA: VAGAL NERVE STIMULATION MARKET, BYAPPLICATION, 2017-2027 (USD MILLION)
TABLE 84 LATIN AMERICA: VAGAL NERVE STIMULATION MARKET, BY END USER, 2017-2027 (USD MILLION)
TABLE 85 THE MOST ACTIVE PLAYER IN THE GLOBAL VAGAL NERVE STIMULATION MARKET
TABLE 86 NEW PRODUCTS LAUNCH/SERVICE DEPLOYMENT
TABLE 87 MERGER & ACQUISITION
TABLE 88 COLLABORATION
TABLE 89 LIVANOVA PLC: PRODUCTS OFFERED
TABLE 90 LIVANOVA PLC: KEY DEVELOPMENTS
TABLE 91 RESHAPE LIFESCIENCES, INC: PRODUCTS OFFERED
TABLE 92 RESHAPE LIFESCIENCES, INC: KEY DEVELOPMENTS
TABLE 93 ELECTROCORE, INC: PRODUCTS OFFERED
TABLE 94 ELECTROCORE, INC: KEY DEVELOPMENTS
TABLE 95 BOSTON SCIENTIFIC CORPORATION: PRODUCTS OFFERED
TABLE 96 BOSTON SCIENTIFIC CORPORATION: KEY DEVELOPMENTS
TABLE 97 NEUROMETRIX INC.: PRODUCTS OFFERED
TABLE 98 NEUROMETRIX INC.: KEY DEVELOPMENTS
TABLE 99 IMTHERA MEDICAL INC.: PRODUCTS OFFERED
TABLE 100 INSPIRE MEDICAL SYSTEMS, INC: PRODUCTS OFFERED
TABLE 101 INSPIRE MEDICAL SYSTEMS, INC.: KEY DEVELOPMENTS
TABLE 102 PARASYM LTD: PRODUCTS OFFERED
TABLE 103 INNOVATIVE HEALTH SOLUTIONS INC.: PRODUCTS OFFERED
 
LIST OF FIGURES
FIGURE 1 MARKET SYNOPSIS
FIGURE 2 MARKET ATTRACTIVENESS ANALYSIS: GLOBAL VAGAL NERVE STIMULATION MARKET
FIGURE 3 GLOBAL VAGAL NERVE STIMULATION MARKET, BY APPLICATION, 2019 (%)
FIGURE 4 GLOBAL VAGAL NERVE STIMULATION MARKET, BY PRODUCTS, 2019 & 2027 (USD MILLION)
FIGURE 5 GLOBAL VAGAL NERVE STIMULATION MARKET, BY APPLICATION, 2019 (%)
FIGURE 6 GLOBAL VAGAL NERVE STIMULATION MARKET, BY APPLICATION, 2019 & 2027 (USD MILLION)
FIGURE 7 GLOBAL VAGAL NERVE STIMULATION MARKET, BY END USER, 2019 (%)
FIGURE 8 GLOBAL VAGAL NERVE STIMULATION MARKET, END USER, 2019 & 2027 (USD MILLION)
FIGURE 9 GLOBAL VAGAL NERVE STIMULATION MARKET ANALYSIS, BY REGION
FIGURE 10 GLOBAL VAGAL NERVE STIMULATION MARKET: MARKET STRUCTURE
FIGURE 11 RESEARCH PROCESS OF MRFR
FIGURE 12 DROC ANALYSIS OF GLOBAL VAGAL NERVE STIMULATION MARKET
FIGURE 13 DRIVERS IMPACT ANALYSIS: VAGAL NERVE STIMULATION MARKET
FIGURE 14 RESTRAINTS IMPACT ANALYSIS: VAGAL NERVE STIMULATION MARKET
FIGURE 15 SUPPLY / VALUE CHAIN: GLOBAL VAGAL NERVE STIMULATION MARKET
FIGURE 17 GLOBAL VAGAL NERVE STIMULATION MARKET, BY PRODUCTS, 2019 & 2027 (USD MILLION)
FIGURE 18 GLOBAL VAGAL NERVE STIMULATION MARKET, BY APPLICATION, 2019 & 2027 (USD MILLION)
FIGURE 19 GLOBAL VAGAL NERVE STIMULATION MARKET, BY END USER, 2019 & 2027 (USD MILLION)
FIGURE 20 GLOBAL VAGAL NERVE STIMULATION MARKET SHARE, BY REGION, 2019 (%)
FIGURE 21 GLOBAL VAGAL NERVE STIMULATION MARKET, BY REGION, 2019 & 2027 (USD MILLION)
FIGURE 22 NORTH AMERICA: VAGAL NERVE STIMULATION MARKET SHARE, BY COUNTRY, 2019 (% SHARE)
FIGURE 23 EUROPE: VAGAL NERVE STIMULATION MARKET SHARE, BY COUNTRY, 2019 (% SHARE)
FIGURE 24 ASIA-PACIFIC: VAGAL NERVE STIMULATION MARKET SHARE, BY COUNTRY, 2019 (% SHARE)
FIGURE 25 REST OF THE WORLD: VAGAL NERVE STIMULATION MARKET SHARE, BY REGION, 2019 (% SHARE)
FIGURE 26 GLOBAL VAGAL NERVE STIMULATION MAJOR PLAYERS MARKET SHARE ANALYSIS, 2019 (%)
FIGURE 27 BENCHMARKING OF MAJOR COMPETITORS
FIGURE 28 MAJOR STRATEGY ADOPTED BY KEY PLAYERS IN GLOBAL VAGAL NERVE STIMULATION MARKET
FIGURE 29 SALES & OPERATING INCOME 2019
FIGURE 30 MAJOR PLAYERS R&D EXPENDITURE 2019
FIGURE 31 LIVANOVA PLC: FINANCIAL OVERVIEW SNAPSHOT
FIGURE 32 LIVANOVA PLC: SWOT ANALYSIS
FIGURE 33 RESHAPE LIFESCIENCES, INC: FINANCIAL OVERVIEW SNAPSHOT
FIGURE 34 RESHAPE LIFESCIENCES, INC: SWOT ANALYSIS
FIGURE 35 ELECTROCORE, INC: FINANCIAL OVERVIEW SNAPSHOT
FIGURE 36 ELECTROCORE, INC: SWOT ANALYSIS
FIGURE 37 BOSTON SCIENTIFIC CORPORATION: FINANCIAL OVERVIEW SNAPSHOT
FIGURE 38 BOSTON SCIENTIFIC CORPORATION: SWOT ANALYSIS
FIGURE 39 NEUROMETRIX INC.: FINANCIAL OVERVIEW SNAPSHOT
FIGURE 40 NEUROMETRIX INC.: SWOT ANALYSIS
FIGURE 41 IMTHERA MEDICAL INC.: SWOT ANALYSIS
FIGURE 42 INSPIRE MEDICAL SYSTEMS, INC: FINANCIAL OVERVIEW SNAPSHOT
FIGURE 43 INSPIRE MEDICAL SYSTEMS, INC.: SWOT ANALYSIS
FIGURE 44 PARASYM: SWOT ANALYSIS
FIGURE 45 INNOVATIVE HEALTH SOLUTIONS INC.:SWOT ANALYSIS
$1,076.83 Million
10.30%
North America
2020-2027
Vagal Nerve Stimulation Market Forecast
The Vagal Nerve Stimulation (VNS) market is expected to cross USD 1,076.83 million by 2027 at a CAGR of 10.30%.
Market Overview:
Vagal nerve stimulation is a procedural treatment to treat patients with epilepsy. In this process, an electrode is implanted in the neck of the patient to deliver electrical impulses to the vagus nerve. It is a non-surgical alternative to surgical removal of brain tissue for the control of epileptic seizures.The seizures of epilepsy are triggered by uncontrolled electrical discharges spreading through the brain. The nerve stimulation process uses a different approach as it provides intermittent electrical stimulation to a nerve outside the brain, which influences certain patterns of brain activity. In contrast with anti-seizure drugs, the effectiveness of healing patients with epilepsy through vagal nerve stimulation is expected to impact the vagal nerve stimulation (VNS) market positively.
The Vagal Nerve Stimulation (VNS) market is mainly driven by the increasing prevalence of neurological disorders and risinginvestment of biotechnology and pharmaceutical industries in R&D. However, factors such as the higher cost of the vagal nerve stimulation treatment procedure are expected to restrict the market's growth during the forecast period. Furthermore, the increasing strategic mergers and acquisitions will create opportunities for market participants.
COVID-19 Analysis:
The COVID-9 has a significant impact on the production of vagal nerve stimulation devices. Due to the pandemic, many countries have imposed a lockdown that has hugely hampered their production processes. The 1Q, 2Q, and 3Q have been most affected by the pandemic. Also, the disruption in the supply chain networks has affected them hugely due to the disruption in their raw material supplies. The remote working of the pandemic has hugely affected the VNS device's production in the COVID-19 pandemic period.
The losses that occurred due to the pandemic have enabled manufacturers to change the pricing structure. The pricing structures of all products are dependent on production expenses, research and development activities, supply chain costs, and inventory costs. The pandemic and effective lockdowns implemented by countries such as the United States, China, India, Japan, Germany, the United Kingdom, and others have impacted inventory management, production lines, labor, and supply chains in the market. Also, the priority treatment of COVID-19 patients has affected the treatment of neurological disorder patients. This has largely affected the vagal nerve stimulation market. However, the lack of inventory management, supply chain disruptions, and growing labor costs have increased the production and distribution costs of the VNS devices. As a result, VNS prices have risen. The VNS therapy and device costs are expected to increase by 2% to 3% due to the COVID-19 impact.
Market Dynamics:
Market Drivers
According to WHO estimates, neurological disorders cause 4.5%-11% of all illnesses, whether in low- or high-income countries.This number is higher than the number of respiratory diseases, gastrointestinal disorders, or cancers, and the burden is likely to increase further over the coming years. The US has also shown a considerable increase in neurological disorders and is expected to continue this growth trend over the next 20 years. The prevalence of such neurological disorders has been estimated to vary from 0.9% to 4% (970–4100 per 100,000 population) with an average of around 2.3% (2390 per 100,000 population). Epilepsy is one of the most widespread neurological disorders, affecting nearly every country on the planet. Countries such as India and China have seen the highest number of populations suffering from this condition. This increasing prevalence has led to the growing demand for various devices and therapies, including vagal nerve stimulation (VNS). Vagal nerve stimulation is used to treat a growing number of neurological disorders. It helps to treat neurological disorders such as epilepsy, depression, and other clinical applications. Because of the high prevalence of neurological disorders around the world, VNS can be used during the forecast period.
Market Restraints
The growing incidents of various neurological disorders, including depression, epilepsy, and other conditions, are driving the adoption of VNS devices and therapies across the globe. As per the Epilepsy Foundation, the VNS therapy currently costs approximately USD 30,000, including the implant and surgical procedure. Also, there are limited numbers of patients undergoing treatment for such neurological conditions, which has highly impacted the cost structure of the VNS treatment as a large number of patients still prefer medical treatment for such neurological disorders. This factor highly affects the adoption of VNS devices and treatments. Moreover, the high cost associated with VNS surgery is significantly affecting the adoption of VNS devices. Conclusively, the high cost of VNS therapy, huge surgery costs, and preferred medical treatments are expected to hinder the growth of the vagal nerve stimulation market during the forecast period.
Market Opportunities
The growing number of neurological disorders has enabled the rapid adoption of vagal nerve stimulation. In addition, increased research & development has led to the new technological advance products coming in the market. Massive investments are assisting start-up companies in developing competitive products for vagal nerve stimulation therapies and surgery.Moreover, the growing number of patents for the VNS from the new start-up companies is expected to enable them to contribute to a high market share in the vagal nerve stimulation market. However, as these upcoming start-up companies have a high-skilled workforce and advanced products, they provide significant strategic mergers and acquisition opportunities for the large players in the market. The large market players should invest in such upcoming start-ups and guide them to achieve their goals in strategic ways. Itis expected to bring various developments in the market and enable large companies to lead the market during the forecast period. Therefore, the increasing strategic mergers and acquisitions are expected to provide a lucrative growth opportunity for the vagal nerve stimulation market during the forecast period.
Vagal Nerve Stimulation (VNS) Market Share (%), by Products, 2019
Source: MRFR Analysis
Value Chain Analysis
The vagal nerve stimulation market is growing steadily and is expected to continue growing at the same rate in the near future. This is due to the growing contribution of existing players to making the products more effective. The supply chain analysis for the vagal nerve stimulation market comprises four major components, which start with research and product development, followed by manufacturing of the products, distribution & sales, and ends with post-sales monitoring.
The key market players focus on incorporating innovations into their current techniques to keep any discrepancies at bay. In May 2020, LivaNova PLC published a new study in the International Journal of Bipolar Disorders based on Vagus Nerve Stimulation Therapy (VNS Therapy) for Treatment As Usual (TAU). This has considerably improved the outcomes for patients suffering from Treatment-Resistant Bipolar Depression (TRBD).
Segment Overview
The Vagal Nerve Stimulation (VNS) market has been divided based on products, application, and end user.
By Products
The implantable vagal nerve stimulator is a device that controls seizures for some people with epilepsy. Unlike other types of epilepsy surgery that involve surgery on the brain or cutting an area of the brain, the implantable vagal nerve stimulator device uses electrical stimulation through the vagal nerve in the neck to reduce subjection. The effectiveness of healing patients without any surgery is a major driver for the significant growth of implantable vagal nerve stimulator devices.
The external Vagal Nerve Stimulation (VNS) devices rely completely on electrical signals that can be passing through the skin and muscles of the neck without affecting the tissue it is passing through. This procedure must be precise enough to regulate and access specific activity of the nerve. Growth in technology and the introduction of new external VNS devices are expected to fuel the growth of the vagal nerve stimulator market.
By Application
On the basis of application, the market is bifurcated into depression, epilepsy, and others.
Depression is a neurological disorder that creates a persistent feeling of sadness and loss of interest. It affects how an individual feel, behaves, and thinks. Depression can lead to a variety of physical and emotional problems. Depression occurs with symptoms such as angry outbursts, irritability or frustration, sleep disturbances, including insomnia, and many others. People with depression usually show severe symptoms to cause evident problems in daily activities, such as work, school, social activities, or relationships with others. With proper diagnosis, therapy, and effective medication, depression can be cured. With technological advancements in the healthcare sector now depression can be cured effectively by using stimulation therapies such as nerve stimulation devices.
Epilepsy is a neurological disorder in which brain activity becomes abnormal, causing seizures or periods of unusual behavior and loss of awareness and sensations. Epilepsy affects both males and females of all races, ages, and ethnic backgrounds. Treatment with medications or surgery can control seizures for people with epilepsy.
Apart from the above applications of vagal nerve stimulation devices, many other neurological disorders can be cured or treated with the help of these devices. Some of them include trauma, headache, very low blood sugar, and loss of consciousness.
By End User
The vagal nerve stimulation market on the basis of the end user is divided into hospitals, ambulatory surgical centers, and others. The emergence of multispecialty clinics for neurology, cardiology, and other critical conditions in developed countries is expected to drive the vagal nerve stimulation market.
The vagal nerve stimulator is used widely in hospitals worldwide to treat epilepsy that is not controlled with normal medication. The nerve stimulation treatment prevents the frequency of seizures by sending mild electrical impulses through the vagal nerve to the brain. VNS treatment helps the patient recover fast, with less intense seizures, improved quality of life, and alertness.
The ambulatory surgical centers are the facilities where surgeries that do not require hospital admission are performed. Ambulatory surgical centers provide a suitable environment and cost-effective services, which are less stressful than many hospitals can offer. Patients choosing to have surgery in an ambulatory surgical center arrive on the day of their procedure, have their surgery in a fully equipped operating room, and recover under the care of skilled nurses, all without any hospital admission.
Apart from the above given end-user segments, the vagal nerve stimulation devices are used for various research projects by government research institutes and commercial organizations. These firms focus on innovating the existing products line to offer enhanced services. The development of healthcare facilities in major developing countries is expected to help grow the market in the years to come.
Vagal Nerve Stimulation (VNS) Market Share, by Region, 2019 (%)
Source: MRFR Analysis
Regional Analysis
The vagal nerve stimulation (VNS) market, based on region, has been divided into North America, Europe, Asia-Pacific, and the Rest of the World.
North America:
North America accounted for a market size of USD 326.35 million in 2019 and is expected to exhibit a CAGR of 9.87% during the forecast period. North America is divided into the US and Canada. North America is expected to dominate the vagal nerve stimulation market due to well-developed technology, increasing prevalence of neurological disorders, rising healthcare spending, and increasing government support for research & development. Moreover, increasing R&D activities and the presence of major companies have fueled the growth of the market in this region. Companies in the US, such as Innovative Health Solutions Inc., announced FDA approval for its IB-Stim to reduce abdominal pain in children suffering from irritable bowel syndrome (IBS).
Europe:
Europe holds the second position in the vagal nerve stimulation market. This is due to the high government support and funding for research & development. Availability of funds for research will drive the market in Europe region over the review period. However, the high cost of neurostimulators and lack of skilled professionals are expected to stun the growth of the vagal nerve stimulation market in this region.
Asia-Pacific:
The Asia-Pacific vagal nerve stimulation market is anticipated to register the second-highest growth rate at a CAGR of 10.69% over the forecast period from 2020 to 2027. Asia-Pacific is the fastest-growing vagal nerve stimulation market after Europe due to the presence of swiftly developing healthcare technology, a large patient population, and high healthcare expenditure. Furthermore, growing opportunities in countries like India, Japan, China, and South Korea will make this an emerging, growing market across the globe.
Rest of the World:
The Rest of the World vagal nerve stimulation market is segmented into two major regions, namely the Middle East & Africa and Latin America. Latin America held the largest market share in 2019, valued at USD 15.08 million, and is expected to grow to USD 24.90 million by 2027. Countries in the Middle East, Africa, and Latin America are major contributors to the vagal nerve stimulation market in this region. The Middle East & Africa have a slightly lower share than Latin America due to the limited availability of medical facilities, limited availability of funds, and poor political conditions in Africa. However, Latin American countries are expected to have potential growth opportunities owing to the development of healthcare facilities in the developing countries of this region.
Competitive Landscape
The vagal nerve stimulation market is profitable, both for existing players as well as new entrants. The market is highly competitive, with all the players contesting to gain market share. Intense competition, rapid technological advances, frequent changes in government policies, and environmental regulations are key factors that confront market growth. A substantial level of rivalry is noted among the existing manufacturers in the market.
Vendors with better technical and financial resources could develop innovative products. Therefore, vendors must develop new technologies to stay up-to-date of emerging technologies that could affect the continuing competitiveness of their product lines in the market.
List of Key Companies Covered in this report:
Recent Developments
Report Overview:
The study examines current short- and long-term market effects, assisting decision-makers in developing short- and long-term business plans by region. North America, Europe, Asia-Pacific, and the Rest of the World are all covered in the report. Market drivers, restraints, opportunities, challenges, Porter's Five Forces, Value Chain, and COVID-19's impact on the market are all examined in this research.
Scope of the Report & Segmentation
Vagal Nerve Stimulation (VNS) Market, by Products
Vagal Nerve Stimulation (VNS) Market, by Application
Vagal Nerve Stimulation (VNS) Market, by End User
Vagal Nerve Stimulation (VNS) Market, by Region
Report Attribute/Metric | Details |
---|---|
Market Size | 2027: USD 1,076.83Million |
CAGR | 10.30% |
Base Year | 2019 |
Forecast Period | 2020-2027 |
Historical Data | 2017 & 2018 |
Forecast Units | Value (USD Million) |
Report Coverage | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends |
Segments Covered | Products, Application, End User, and Region |
Geographies Covered | North America, Europe, Asia-Pacific, Rest of the World |
Key Vendors | • LivaNova, PLC (UK) • ReShape Lifesciences Inc (US) • ElectroCore Medical LLC (US) • Boston Scientific Corporation (US) • NeuroMetrix, Inc. (US) • ImThera Medical, Inc. (US) • Inspire Medical Systems, Inc (US) • Parasym Ltd (UK) • Innovative Health Solutions, Inc. (US) |
Key Market Opportunities | • Increasing strategic mergers and acquisition |
Key Market Drivers | • Increasing prevalence of neurological disorders • Increasing investment of biotechnology and pharmaceutical industries in R&D |
Frequently Asked Questions (FAQ) :
The Vagal Nerve Stimulation (VNS) Market is predicted to have a CAGR of 8.68% during the forecast period of 2017 to 2023.
The Vagal Nerve Stimulation (VNS) Market would suffer from high treatment costs.
The end users are ambulatory surgical centers, hospitals, and others.
The application-segment includes migraine, epilepsy, depression, and others.
The products included are VNS devices and external VNS devices.